GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
brentuximab vedotin is an approved drug (FDA (2011), EMA (2012))
Compound class:
Antibody
Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. US FDA (2011) | EU EMA (2012) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9144 | brentuximab vedotin |
Synonyms ![]() |
| Adcetris® | anti-CD30 ADC SGN-35 | SGN 35 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 324 |
| Other databases | |
| GtoPdb PubChem SID | 178103378 |
| PubChem SID | 178103378 |
| Search PubMed clinical trials | brentuximab vedotin |
| Search PubMed titles | brentuximab vedotin |
| Search PubMed titles/abstracts | brentuximab vedotin |
| Wikipedia | Brentuximab_vedotin |